Tumor Research

mAb anti Human PD-L1 clone 12D9

Catalogue #: MO-L40044O

Product Name Price Qty
mAb anti human PD-L1 clone 12D9, 0.1mg
$220.00
mAb anti human PD-L1 clone 12D9, 0.5mg
$360.00

Mouse monoclonal antibody to human PD-L1, Clone 12D9

Description

Details

Description: Mouse monoclonal antibody (mAb) to human programmed death ligand 1 (PD-L1), or mouse mAb to B7H1, or mouse mAb to human CD274.

Purification: Protein G affinity purified

Target Protein: Human programmed death ligand 1 (PD-L1), also known as B7H1 or CD274.

Immunogen: Human cell expressed recombinant PD-L1 (Phe19-Arg238) with poly-histidine tag at C-terminus.

Fusion Myeloma: SP2/0

Specificity: Reactive with human programmed death ligand 1 (PD-L1).

Species Reactivity: Human, others not tested.

Host / Isotype: Mouse, IgG1 Kappa

Formulation: Lyophilized from a solution in 0.01M PBS, pH 7.0

Reconstitution: Double distilled water is recommended to reconstitute the antibody to 1mg/mL.

Storage: Store at -20oC

Research Area: Immunosuppression. Cancer immunotherapy.

Background:

Programmed Death Ligand 1 (PD-L1), a 40KD transmembrane protein, is a ligand of immune checkpoint protein Programmed Death-1 (PD-1). During T-cell receptor signalling, the binding of PD-L1 to PD-1 transmits an inhibitory signal to activated T-cells to decrease their proliferation. PD-L1 is also believed to play a role in the generation and regulation of Treg cells, and in the enhancement of Treg cell function. PD-L1/PD-1 pathway is important to immune suppression, such as self-tolerance, suppression of immune-rejection during pregnancy and allograft, and immune evasion by cancers. Upregulation of PD-L1 has been found to be associated with many cancer types. For example, increased PD-L1 expression has been shown to be related to tumor aggressiveness and higher mortality in patients with renal cell carcinoma, and related to significantly poorer prognosis and lower intraepithelial CD8+ T-lymphocyte count in patience with ovarian cancer. Antibodies that block the PDL-1 /PD-1 pathway have been extensively studied in clinical trials, and some have been approved as immunotherapy for cancer.  

Applications: 

ELISA: Indirect ELISA: The antibody reacts with recombinant PD-L1 in indirect ELISA. 

Western blot: Western Blot: Anti-PD-L1 clone 12D9 detected 40ng recombinant PD-L1 on Western Blot. The blot was stained with HRP substrate 4-Chloro-1-Naphthol.

References:

If research is published using this product, please inform Anogen in order to cite the reference on this datasheet. Anogen will provide one unit of product in the same category as gratitude.

Additional

Additional Information

Product Specificity mAb anti Human PD-L1/B7H1/CD274, 12D9
Application EIA, WB
Size 0.1 mg
Contact Us